Assessing Preference-Based Outcome Measures for Overactive Bladder:An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial by Herdman, Mike et al.
                          Herdman, M., Nazir, J., Hakimi, Z., Siddiqui, E., Huang, M., Pavesi, M., ...
Devlin, N. (2017). Assessing Preference-Based Outcome Measures for
Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from
the BESIDE Clinical Trial. Patient, 10(6), 677-686.
https://doi.org/10.1007/s40271-017-0262-8
Peer reviewed version
Link to published version (if available):
10.1007/s40271-017-0262-8
Link to publication record in Explore Bristol Research
PDF-document
This is the accepted author manuscript (AAM). The final published version (version of record) is available online
via Springer at DOI: 10.1007/s40271-017-0262-8. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1 
Assessing Preference-Based Outcome Measures for Overactive 
Bladder: An Evaluation of Patient-reported Outcome Data from the 
BESIDE Clinical Trial 
 
Mike Herdman,1 Jameel Nazir,2 Zalmai Hakimi,3 Emad Siddiqui,2 Moses Huang,2 
Marco Pavesi,4 Scott MacDairmid,5 Marcus. J. Drake,6 Nancy Devlin1 
1Office of Health Economics, London, UK; 2Astellas Pharma Europe Ltd., Astellas 
Medical Affairs, EMEA, HEOR, Chertsey, UK; 3Astellas Pharma Europe B.V., 
Astellas Medical Affairs, Global, HEOR, Leiden, Netherlands; 4Data Management 
Centre, European Foundation for the study of Chronic LIver Failure (EF-CLIF), 
Barcelona, Spain; 5Alliance Urology Specialists, Greensboro, USA; 6University of 
Bristol and Bristol Urological Institute, Bristol, UK 
 
Address correspondence to: 
Mike Herdman 
The Office of Health Economics 
Southside, 7th Floor 
105 Victoria Street 
London 
SW1E 6QT 
2 
Tel: +44 (0)20 7747 8850 
Mobile: 00 34 677 427 089 
Email: mherdman@ohe.org 
 
Abstract word count: 250 
Text word count: 3006 
 
Short title (100 characters limit) 
• Patient-reported Outcome Data for The Treatment Of Overactive Bladder from 
the BESIDE Clinical Trial 
Key words: Overactive bladder; mirabegron; solifenacin; combination; health-related 
quality of life; responders 
3 
 
COMPLIANCE WITH ETHICAL STANDARDS 
Funding Support: This research was funded by Astellas Pharma Europe Ltd. 
Medical writing support, provided by Lucy Kanan and Tyrone Daniel from Bioscript 
Medical, was funded by Astellas Pharma Europe Ltd. 
Financial Disclosures: JN, ZH, ES and MHu are full-time employees of Astellas 
Pharma; MHe and ND are employees of Office of Health Economics, which was 
contracted by Astellas Pharma to support the conduct of this study, and members of 
the EuroQoL group; SM has received consultancy fees from Astellas; MJD has 
received speaker and advisory board fees, and research funding from Allergan, 
Astellas and Ferring; MP has no conflicts of interest. 
Author Contributions: ND, JN, SM, MJD and ZH proposed key elements of the 
study design and critically reviewed the draft protocol/analysis plan; MP, SM and 
MJD acquired data; ND, MHe, MP, JN, SM, MJD, ES and ZH contributed to the 
analysis and interpretation of the data. All authors discussed the results, provided 
key intellectual input and commented on the manuscript and approved the final 
version for submission. 
 
4 
 
ABSTRACT 
Objectives 
To compare outcomes using two preference-based measures of health status 
(EQ-5D-5L and OAB-5D) in patients with overactive bladder (OAB) treated with 
solifenacin plus mirabegron or solifenacin monotherapy in the BESIDE trial. 
Methods 
Patients with OAB remaining incontinent after 4 weeks’ treatment with solifenacin 
5 mg were randomized 1:1:1 to combination treatment (solifenacin 5 mg plus 
mirabegron [25 mg for the first 4 weeks/50 mg for the last 8 weeks]), solifenacin 
5 mg, or solifenacin 10 mg. EQ-5D-5L and OAB-q were administered at baseline, 
weeks 4, 8, 12 and end of treatment (EoT). OAB-5D scores were derived from 
OAB-q results. Responder analysis was carried out using several definitions of 
minimally important difference. 
Results 
2054 patients received ≥1 dose of study treatment (combination, n = 694; solifenacin 
5 mg, n = 684; solifenacin 10 mg, n = 676). EQ-5D-5L Index mean score changes 
(from baseline to EoT) were greater with combination (0.059) compared with 
solifenacin 5 mg (0.040) and 10 mg (0.044) monotherapy, but the differences were 
not statistically significant. A significantly greater improvement was observed for 
combination on OAB-5D (0.107 vs 0.085 for 5 mg and 0.087 for 10 mg; p ≤ 0.01). 
The dimensions most improved overall were anxiety/depression, pain/discomfort and 
usual activities on EQ-5D-5L, and urge, urine loss and coping on OAB-5D. The 
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proportion of responders was significantly greater with combination compared with 
monotherapy using OAB-5D only. 
Conclusions 
Improvements were observed in all study arms on both the EQ-5D-5L and OAB-5D, 
although only the OAB-5D showed a statistically significant benefit for combination 
versus solifenacin monotherapy. Combining generic and condition-specific 
preference-based health status measures allows for assessment of dimensions 
which are particularly relevant to this patient population, while permitting comparison 
with outcomes from other studies, treatments and populations via EQ-5D. 
 
Key points 
• Both solifenacin alone and solifenacin plus mirabegron improve health-related 
quality of life after 12 weeks of treatment in patients with overactive bladder 
• The improvement in health-related quality of life is significantly greater with 
solifenacin plus mirabegron compared with solifenacin alone 
• Significant differences between the study arms was observed with the 
condition-specific measure of health-related quality of life (OAB-5D) but not 
the generic measure (EQ-5D-5L) 
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1 Introduction 
Overactive bladder (OAB) is a common and debilitating condition, defined as urinary 
urgency with/without urgency urinary incontinence, usually with increased daytime 
frequency and nocturia in the absence of proven infection or other obvious pathology 
[1]. OAB symptoms compromise health-related quality of life (HRQoL) and negatively 
affect sleep quality, social activities, self-esteem, relationships, work productivity, 
physical exercise, psychological health, and sexual activity/enjoyment [2-5]. Among 
OAB symptoms, urgency urinary incontinence – present in approximately one-third 
of OAB cases – has the greatest negative impact on HRQoL and has a major 
socioeconomic impact [2,6]. 
Mirabegron is a selective β3-adrenoreceptor agonist, which relaxes bladder 
smooth muscle and increases bladder storage capacity [7]. Multiple Phase III trials 
have demonstrated the efficacy and tolerability of this agent in patients with OAB 
[8-10], and mirabegron is indicated for the treatment of urgency, increased 
micturition frequency and/or urgency incontinence [11]. 
Antimuscarinic agents and mirabegron represent standard of care 
pharmacological treatment options for OAB. Although the two drug classes provide 
similar efficacy, mirabegron is not associated with bothersome, typical anticholinergic 
side effects such as dry mouth [12]. OAB is a chronic condition which often requires 
long-term management. The occurrence of anticholinergic side effects can 
potentially limit the use of antimuscarinics in patients among whom symptoms persist 
[13]. It is therefore of interest to investigate whether the addition of mirabegron, with 
its different mechanism of action, may improve OAB symptoms, without the need for 
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antimuscarinic dose escalation and potential concomitant increase in anticholinergic 
burden and adverse effects. 
The evaluation of new medical treatments and technologies increasingly involves 
analysis of their cost-effectiveness and cost-utility – these analyses form an integral 
part of health technology assessment (HTA). In many countries, cost-utility analysis 
(CUA) can also be critical to decision-making on reimbursement. Within the CUA 
framework, preference-based measures (PBMs) of health status provide a 
multidimensional description of health to which societal preference weights (or 
utilities) can be attached. These preference weights can then be used in combination 
with survival data to generate quality-adjusted life-years [14]. One widely used PBM 
is the EQ-5D, a simple instrument measuring five dimensions of health status, which 
is the preferred measure of the National Institute for Health and Care Excellence in 
England/Wales [15]. Although of great value, generic PBMs (e.g., EQ-5D), which are 
applicable to a wide range of patient groups and conditions, may not capture all 
aspects of health status relevant to patients with a particular condition. In such 
cases, condition-specific PBMs are sometimes developed, e.g., the OAB-5D for 
patients with OAB [16]. Given that both EQ-5D and OAB-5D could potentially be 
used to generate utilities for OAB, and given the importance of CUA in HTA and 
treatment funding discussions, it is critical to understand how the two instruments 
perform comparatively.  
The inclusion of the latest version of EQ-5D (i.e., EQ-5D-5L), which has five 
response levels for each of the five dimensions [17], and OAB-5D in a recent 
Phase III trial of OAB (BESIDE [18]) provided an opportunity for such a comparison 
within an exploratory analysis presented here. This was the first time that EQ-5D-5L 
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has been compared head-to-head with OAB-5D, and the first time that the new 
EQ-5D-5L value set for England has been reported in an OAB patient population.   
2 Materials and Methods 
2.1 Study Design and Patients 
BESIDE was a randomized double-blind multicenter Phase IIIb trial (NCT01908829) 
that included multiple investigator sites in Europe, the United States, Canada, 
Australia and Lebanon; the methods have been published previously [18]. In brief, 
patients aged ≥18-years-old with OAB symptoms for >3 months, including an 
average of ≥2 incontinence episodes/24 hours, entered a 2-week screening/wash-
out period to remove the effects of previous OAB medication and to familiarize with 
the patient-recorded electronic micturition diary. Patients then underwent 4-week 
single-blind treatment with solifenacin 5 mg/day. Patients still experiencing ≥1 
incontinence episode during a 3-day diary were eligible for randomization (1:1:1) to 
12 weeks of combination treatment (solifenacin 5 mg/day plus mirabegron 
25 mg/day for 4 weeks then mirabegron 50 mg/day for the remaining 8 weeks), 
solifenacin 5 mg/day or 10 mg/day. 
The primary publication reported that the combination significantly reduced daily 
incontinence episodes (primary endpoint; −1.80 versus −1.53, p < 0.01), daily 
micturitions (−1.59 versus −1.14, p < 0.01) and incontinence episodes over 3 days 
(4.25 versus 4.87, p = 0.01) compared with solifenacin 5 mg [18]. The combination 
was non-inferior to solifenacin 10 mg for both key secondary endpoints (daily 
micturitions [−1.59 versus −1.12, p < 0.01] and incontinence episodes over 3 days 
[4.25 versus 4.72, p = 0.13]) and superior to solifenacin 10 mg for daily 
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micturition[18]. In addition, the incidence of dry mouth with the combination was 
similar to solifenacin 5 mg [18]. 
2.2 Patient-reported outcome measures 
The following patient reported outcome (PRO) measures were included in the 
BESIDE trial: the OAB questionnaire (OAB-q), from which OAB-5D preference-
based scores can be derived; the patient perception of bladder condition (PPBC) 
questionnaire; the treatment satisfaction visual analog scale (TS-VAS); the patient 
and clinician global impression of change (PGIC and CGIC) scales; and the 
EQ-5D-5L. The analysis in the present paper reports  on the EQ-5D-5L, OAB-5D, 
PGIC and CGIC; outcomes from the PPBC, TS-VAS and OAB-q are reported 
separately [19].  
EQ-5D-5L measures health status in five dimensions: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression [17]. Each dimension has five 
response levels (1 to 5): no problems, slight/mild problems, moderate problems, 
severe problems and extreme problems/unable to perform activity. Respondents are 
asked to indicate their health status on the day of administration by selecting the 
most appropriate response for each dimension. The 1-digit numbers for each 
dimension are then combined to provide a 5-digit descriptive profile of the 
respondent’s overall health state. Societal preference weights generated using 
trade-off techniques are available in the form of a single index value for each of the 
3125 possible EQ-5D-5L health states. In the current analysis, EQ-5D-5L index 
values were calculated using the recently developed value set for England [20,21], 
with scores which range from –0.281 (worst possible health state, i.e., 55555) to 1 
(best possible health state/full health, i.e., 11111).  
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OAB-5D was derived from OAB-q – a 33-item condition-specific questionnaire 
that consists of an eight-item symptom bother scale and a 25-item health status 
utility measure scale [22]. OAB-5D is a reduced health state classification system 
that includes five dimensions (urge to urinate, urine loss, sleep impact, coping 
strategy, and concern with urinary problems) with five severity levels (ranging from 1 
denoting no problem to 5 indicating an extreme problem) [16]. Like EQ-5D-5L, OAB-
5D generates descriptive profiles representing 3125 unique health states which were 
translated into a single index value using trade off techniques in a representative 
sample of the UK population [23].  
PGIC and CGIC evaluate health status using a simple seven-point single-item 
scale ranging from ‘very much improved’ to ‘very much worse’. On PGIC, each 
patient rated any change in his/her bladder symptoms and general health from 
baseline, whereas CGIC was rated by clinicians based on changes they observed in 
the patient's bladder symptoms.  
Data for the EQ-5D-5L and OAB-5D questionnaires were collected at baseline, at 
weeks 4, 8 and 12, and end of treatment (EoT); PGIC and CGIC data were collected 
at EoT only.  
2.3 Responder Analyses 
Responder analyses were performed to determine the number and proportion of 
patients who achieved at least a minimally important difference (MID), or 
improvement, on EQ-5D-5L or OAB-5D. The MID can be defined as the smallest 
change that is perceived by patients as beneficial or that would result in a change in 
treatment [24]. However, there are multiple ways of estimating a MID and they 
usually give a range of possible values. There are no previously published MID 
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values for EQ-5D-5L or OAB-5D, and we used several approaches to estimating 
them for the present study. As there is no agreement on which method for estimating 
MIDs is the most appropriate for health status utility measures, such as those used 
here, we performed several responder analyses using the different MIDs derived for 
the current analysis. For EQ-5D-5L, a responder was defined by an incremental 
improvement from baseline to EoT of at least: (a) 0.017, i.e., the mean increment in 
patients who reported at least minimally improved health on the PGIC index; (b) 
0.102, i.e., 0.5 standard deviation (SD) of the mean index value for the total study 
population at baseline; and (c) 0.065, i.e., mean change in utility associated with a 
one-level change in any dimension of the descriptive system (e.g., 11112 vs 11113) 
as described in Luo et al [25]. The same approaches were applied to OAB-5D, 
generating MIDs of: (a) 0.054; (b) 0.043; and (c) 0.020, respectively. In addition, 
double responder analyses were conducted for EQ-5D-5L and OAB-5D by 
combining the data for two definitions of MID described above, i.e. assessing the 
proportion of patients who achieved two MIDs (e.g. EQ-5D-5L ≥0.017 and OAB-5D 
≥0.054). 
2.4 Statistical Analyses 
EQ-5D-5L and OAB-5D data were analyzed using a modified full analysis set 
(mFAS, defined as all randomized patients [after 4-week solifenacin run-in] who 
received ≥1 dose of double-blind treatment, had ≥1 micturition at and after baseline, 
had ≥1 incontinence episode at baseline, and completed the EQ-5D-5L 
questionnaire at baseline and at least once post-baseline). Patients with missing 
baseline EQ-5D-5L values were excluded; missing values at EoT were imputed 
using last observation carried forward. Analyses were also performed using a per 
protocol set (PPS), which included all patients in the mFAS except those meeting 
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additional exclusion criteria (Supplementary Table 1). Categorical variables were 
summarized by counts and percentages and compared between treatments by Chi-
square tests, while mean (SD) and Student’s t tests were used for continuous 
variables. Analysis of covariance (ANCOVA) models were used to compare changes 
in EQ-5D--5L and OAB-5D index scores from baseline to EoT, adjusting for the 
following covariates: baseline index score, sex, age, geographic region and 4-week 
incontinence reduction (yes/no). Spearman's correlation estimate analyses were 
performed between the PGIC and CGIC data and the EQ-5D-5L and OAB-5D index 
data. 
3 Results 
The mFAS included 2054 patients (combination, n = 694; solifenacin 5 mg, n = 684; 
solifenacin 10 mg, n = 676). Overall, 1902 patients comprised the PPS (combination, 
n = 631; solifenacin 5 mg, n = 640; solifenacin 10 mg, n = 631). Similar baseline 
demographic and clinical characteristics were observed across the three treatment 
arms in the mFAS (Table 1) and PPS. 
3.1 EQ-5D-5L and OAB-5D indices 
The mean change with EQ-5D-5L index from baseline to EoT was statistically 
significant for combination therapy (0.059; adjusted p < 0.01), solifenacin 5 mg 
(0.040; adjusted p < 0.01) and solifenacin 10 mg (0.044; adjusted p < 0.01) (Fig. 1A); 
the magnitude of change was not statistically significant for combination therapy 
versus solifenacin 5 mg (adjusted p = 0.12) and solifenacin 10 mg (adjusted p = 
0.11). The proportion of patients with EQ-5D-5L scores indicating full health/no 
problems on any dimension (i.e., 11111 profile) increased at EoT (43–47 %) versus 
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baseline (29–30 %) and was similar across the three treatment arms (Supplementary 
Table 2). 
Using OAB-5D, the improvement in health status from baseline to EoT was 
significantly greater with the combination (0.107; adjusted p < 0.01), solifenacin 5 mg 
(0.085; adjusted p < 0.01) and solifenacin 10 mg (0.087; adjusted p < 0.01) (Fig. 1B), 
and with the combination versus solifenacin 5 mg (adjusted p < 0.01) and solifenacin 
10 mg (adjusted p < 0.01). The proportion of patients with OAB-5D scores reporting 
full health was greater at EoT (9–13 %) versus baseline (0–1 %) and was similar at 
both time points across the three treatment arms (Supplementary Table 2). The 
dimension score results based on the PPS were similar to mFAS (data not shown). 
3.2 Questionnaire Dimensions: EQ-5D-5L and OAB-5D 
The EQ-5D-5L dimensions showing most improvement in terms of the proportion of 
patients who switched from reporting problems at baseline to ‘no problems’ at EoT 
were anxiety/depression, pain/discomfort and usual activities. This finding was 
common to all three treatment arms (Fig. 2A). The proportion of patients reporting no 
problems in OAB-5D dimensions also increased from baseline to EoT in all three 
treatment arms (Fig. 2B); the largest improvements were observed for the 
combination treatment and were seen on the urge (3 % to 24 %), urine loss (3 % to 
42 %) and coping (8 % to 36 %) dimensions. 
3.3 PGIC and CGIC 
The proportion of patients who reported their bladder symptoms as very much/much 
improved at EoT was higher in the combination group (73.9 %) versus 
solifenacin 5 mg (63.4 % [p < 0.01]) and solifenacin 10 mg (67.3 % [p = 0.01]) 
(Supplementary Table 3). Similar findings were reported for PGIC general health 
14 
(very much/much improved: 58.8 % vs 51.9 % [p = 0.01] and 52.0 % [p = 0.01]) and 
CGIC bladder symptoms (very much/much improved: 74.1 % vs 64.8 % [p < 0.01] 
and 69.0 % [p = 0.03]) with combination, solifenacin 5 mg and solifenacin 10 mg, 
respectively. 
3.4 Responder Analyses 
With EQ-5D-5L, no statistically significant differences in responder rates, according 
to all definitions of MID, were observed between any treatment arms (Table 2). In 
contrast, the combination group showed higher responder rates than solifenacin 
monotherapy according to all definitions of MID using OAB-5D (Table 2); no 
significant differences were observed between solifenacin 5 mg and 10 mg.   
In the double responder analysis, the proportion of responders was 
significantly greater with the combination compared with both solifenacin arms using 
the EQ-5D-5L MID ≥0.017 and the OAB-5D MIDs ≥0.054 and ≥0.043 (all p ≤ 0.05; 
Table 2). The proportion of responders for other combinations of MID definitions was 
numerically greater for the combination compared with solifenacin monotherapies, 
but the differences were not statistically significant. 
3.5 Correlation of EQ-5D-5L and OAB-5D with PGIC and CGIC 
In patients who reported very much/much improvement in PGIC bladder, the change 
in mean EQ-5D-5L index scores was numerically greater in the combination group 
compared with solifenacin 5 mg and 10 mg (0.072 vs 0.064 and 0.058, respectively). 
Similar changes in EQ-5D-5L index scores for combination versus monotherapy 
were observed in patients with very much/much improved PGIC general health 
(0.082 vs 0.067 and 0.068, respectively) and very much/much improved CGIC 
bladder (0.071 vs 0.062 and 0.052) (Supplementary Table 4). A similar pattern of 
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numerically higher OAB-5D index scores was observed with very much/much 
improved PGIC bladder (0.130 vs 0.118 and 0.112, respectively), PGIC general 
health (0.133 vs 0.118 and 0.115, respectively) and CGIC bladder (0.127 vs 0.111 
and 0.108) (Supplementary Table 5). The Spearman’s analysis showed a positive 
correlation (p < 0.01) between ratings on PGIC and EQ-5D-5L and OAB-5D 
(Supplementary Table 6). 
4 Discussion 
Consistent with earlier observations of significantly improved HRQoL via 
OAB-q, PPBC and TS-VAS in BESIDE [19], the present analysis shows that benefits 
were observed in the combination and solifenacin monotherapy arms at EoT 
compared with baseline using both the generic and condition-specific measures. 
These results complement the earlier published findings from the BESIDE trial which 
showed that the combination of solifenacin 5 mg plus mirabegron significantly 
improves symptoms of OAB compared with solifenacin monotherapy in incontinent 
OAB patients [18]. Most notably, the combination was superior to solifenacin 5 mg 
alone in improving symptoms of incontinence among patients who remained 
incontinent despite initial solifenacin 5 mg treatment [18].  
The EQ Index and individual EQ-5D-5L dimensions showed no significant 
differences in the degree of change between study arms. A lack of significant 
difference between study arms on EQ-5D-3L (i.e., five dimensions with three levels) 
was also observed in a pooled analysis of three Phase III studies of mirabegron [26]. 
However, the magnitude of change in EQ-5D Index scores (from baseline to Week 
12) in this earlier study (0.026–0.045) was similar to that observed in the present 
study (0.040–0.059). The fact that EQ-5D-5L is a generic instrument that measures 
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core dimensions of health status, which need to be relevant to a wide range of 
patient groups with differing severity/number of symptoms, may make it less 
sensitive to the type of between-arm differences observed in this OAB patient group. 
The high ceiling effect (29–30 % of patients reported full health at baseline) may 
have also reduced the instrument’s ability to distinguish between groups or to fully 
capture changes over time.  
In contrast, the condition-specific OAB-5D index was more sensitive to 
changes in health status than EQ-5D-5L and showed statistically significant 
differences between treatment arms. These findings are consistent with an earlier 
report of health-state utilities for patients with OAB, which evaluated both measures 
in a pooled analysis of three large, multicenter, placebo-controlled trials [27]. That 
the OAB-5D index is more sensitive than EQ-5D-5L for detecting changes in health 
status is not unexpected, as condition-specific instruments include items of more 
relevance to a particular condition and are likely to be less influenced by natural 
variation in health status unrelated to the specific condition.  
Among OAB symptoms, urgency urinary incontinence is recognized as having 
the greatest negative impact on HRQoL [3]. The most notable improvements 
observed on OAB-5D in the present study were observed in the urge, urine loss and 
coping dimensions – this likely reflects the significant improvements in incontinence 
and micturition symptoms observed with the combination [18]. Together, the data are 
in consonance with the results from recent discrete choice experiments that showed 
patients with OAB have a preference for avoidance of urgency and incontinence 
episodes and reduction in micturition frequency [28,29], and suggest that 
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improvements captured by OAB-5D in the current study occurred to important 
dimensions that are likely of particular relevance to patients with OAB.  
During the BESIDE trial, the combination treatment was well tolerated. In 
particular, the incidence of dry mouth – which is frequently reported with 
antimuscarinics and a common reason for treatment discontinuation – was lower 
with combination versus solifenacin 10 mg and similar to solifenacin 5 mg [16]. A 
treatment which maintains efficacy while constraining side effects is likely to show a 
greater advantage in terms of utility. Although we did not directly analyse the impact 
of dry mouth and other side effects in the present study, a recent publication showed 
that the side effects of antimuscarinic treatment (mainly dry mouth, but also 
constipation) can have a considerable negative impact on EQ-5D utilities [30]. 
For the combination treatment, the change in EQ-5D-5L scores from baseline 
to EoT (0.06) exceeded the threshold value for one of the three MIDs (i.e., 0.017 
based on PGIC) and was approximately the same value as the MID calculated using 
the one-step transition methodology (i.e., 0.065), suggesting that the change 
observed on EQ-5D was meaningful [25]. While there were no statistically significant 
differences in the proportion of responders between the three treatment arms using 
EQ-5D-5L, the differences between arms were significant using OAB-5D, with the 
combination arm reporting the highest rate of responders. Furthermore, on OAB-5D, 
baseline to EoT changes in OAB-5D scores for all three treatments exceeded all the 
MIDs used.  
Study strengths include the fact that the data are derived from a large 
randomized controlled Phase III trial and the use of well-defined health status utility 
measures. This is the first time MIDs have been calculated with the EQ-5D-5L value 
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set for England or with OAB-5D, though further studies are required to confirm these 
values. It should also be noted that these MIDs are specific to the value sets used to 
estimate utilities in the present study and they may not be transferable to other value 
sets or other patient populations. Further studies should also assess the impact of 
combination treatment on HRQoL in males, who were underrepresented in BESIDE, 
and to assess the impact of mirabegron with/without solifenacin on HRQoL in routine 
clinical practice. 
5 CONCLUSIONS 
In this analysis of data from the BESIDE trial, both preference-based health status 
measures analysed showed improvements from baseline to EoT in all three 
treatment arms. However, only the condition-specific measure showed a statistically 
significant benefit for combination treatment versus solifenacin monotherapy.  
Using the more sensitive condition-specific OAB-5D instrument in combination 
with EQ-5D-5L makes it possible to evaluate the impact of treatment on dimensions 
of health status that are important to patients with OAB, while also permitting 
comparisons of outcomes from this study with different disease areas, in which 
EQ-5D-5L is used, that might be important for HTA decision-making. From a clinical 
perspective, use of combination treatment appears to be justified by gains in 
condition-specific HRQoL over and above those achieved with monotherapy.  
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Figure Legends 
Fig 1 Mean scores in EQ-5D-5L (A) and OAB-5D (B) indexes from baseline to EoT 
in the mFAS. 
Patient numbers at baseline* and EoT‡; compared with combination§. 
EoT, end of treatment; mFAS, modified full analysis set (randomized patients [after 
4-week solifenacin run-in] who received ≥1 dose of study treatment and completed 
the EQ-5D-5L questionnaire at baseline and at least once post-baseline). 
 
Fig 2 Proportion of patients with no problems on the EQ-5D-5L (A) and OAB-5D (B) 
dimensions at baseline and at EoT in the mFAS. 
Patient numbers at baseline* and EoT‡. 
EoT, end of treatment; mFAS, modified full analysis set (randomized patients [after 
4-week solifenacin run-in] who received ≥1 dose of study treatment and completed 
the EQ-5D-5L questionnaire at baseline and at least once post-baseline). 
 
26 
 
Table 1 Summary of demographics and baseline characteristics in the mFAS 
 Combination  
(n = 694) 
Solifenacin 5 mg 
(n = 684) 
Solifenacin 10 mg 
(n = 676) 
Sex, female (%) 83.3 83.0 83.9 
Age, years, mean (SD) 58.2 (13.1) 56.8 (13.3) 57.4 (13.2) 
Mean duration of OAB, 
months (SD) 
76.5 (86.7) 67.5 (71.4) 70.8 (77.7) 
No. of incontinence episodes 
during 3-day diary, mean 
(SD) 
9.5 (8.7) 9.3 (8.2) 9.9 (9.2) 
No. of incontinence 
episodes/24 hour, mean (SD) 
3.19 (2.95) 3.14 (2.75) 3.32 (3.06) 
No. of micturitions/24 hour, 
mean (SD) 
9.12 (2.76) 8.89 (2.72) 8.99 (2.76) 
No. of urgency incontinence 
episodes/24 hour, mean (SD) 
 
2.84 (2.72) 
 
2.77 (2.53) 
 
2.88 (2.77) 
No. of pads/24 hour, mean 
(SD) 
1.95 (2.38) 1.90 (2.36) 2.06 (2.58) 
No. of urgency episodes 
(grade 3 or 4)/24 hour, mean 
(SD) 
 
5.74 (3.83) 
 
5.57 (3.60) 
 
5.67 (3.78) 
No. of nocturia episodes/ 
24 hour, mean (SD) 
1.15 (1.13) 1.07 (1.03) 1.15 (1.11) 
mFAS, modified full analysis set, FAS (randomized patients [after 4-week solifenacin run-in] who 
received ≥1 dose of study treatment and completed the EQ-5D-5L questionnaire at baseline and at 
least once post-baseline); OAB, overactive bladder; SD, standard deviation. 
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Table 2 Responder analysis for EQ-5D-5L and OAB-5D at EoT in the mFAS 
 Responder 
definition of MID 
Combination  
(n = 694) 
Solifenacin  
5 mg* 
(n = 684) 
Solifenacin  
10 mg*  
(n = 676) 
Single responders  
 EQ-5D-5L ≥0.102 27 % 26 % 
p = 0.75 
25 % 
p = 0.68 
≥0.065 37 % 34 % 
p = 0.54 
32 % 
p = 0.19 
≥0.017 50 % 46 % 
p = 0.28 
45 % 
p = 0.27 
 OAB-5D ≥0.043 77 % 66 % 
p < 0. 01 
66 % 
p < 0. 01 
≥0.020 84 % 77 % 
p < 0.01 
77 % 
p < 0.01 
≥0.054 74 % 62 % 
p < 0. 01 
62 % 
p < 0. 01 
Double responders 
 EQ-5D-5L 
 OAB-5D 
≥0.017 
≥0.054 
40 % 34 % 
p = 0.03 
33 % 
p = 0.02 
 EQ-5D-5L 
 OAB-5D 
≥0.017 
≥0.043 
42 % 36 % 
p < 0.05 
35 % 
p = 0.03 
 EQ-5D-5L 
 OAB-5D 
≥0.017 
≥0.020 
45 % 39 % 
p = 0.10 
39 % 
p = 0.08 
 EQ-5D-5L 
 OAB-5D 
≥0.102 
≥0.054 
23 % 20 % 
p = 0.23 
20 % 
p = 0.23 
 EQ-5D-5L 
 OAB-5D 
≥0.102 
≥0.043 
24 % 21 % 
p = 0.29 
20 % 
p = 0.29 
 EQ-5D-5L 
 OAB-5D 
≥0.102 
≥0.020 
25 % 23 % 
p = 0.60 
23 % 
p = 0.52 
 EQ-5D-5L 
 OAB-5D 
≥0.065 
≥0.054 
31 % 26 % 
p = 0.07 
25 % 
p = 0.03 
 EQ-5D-5L 
 OAB-5D 
≥0.065 
≥0.043 
32 % 27 % 
p = 0.12 
25 % 
p = 0.03 
 EQ-5D-5L 
 OAB-5D 
≥0.065 
≥0.020 
34 % 30 % 
p = 0.27 
28 % 
p = 0.07 
*, adjusted P-values for combination therapy compared with solifenacin monotherapy. 
EoT, end of treatment; mFAS, modified full analysis set (randomized patients [after 4-week solifenacin 
run-in] who received ≥1 dose of study treatment and completed the EQ-5D-5L questionnaire at 
baseline and at least once post-baseline); MID, minimally important difference. 
